Project Details
| Status | Active |
|---|---|
| Effective start/end date | 1/01/25 → 31/12/25 |
Collaborative partners
- Rīga Stradiņš University (lead)
- Tartu University and University Hospital of Tartu (Project partner)
A Phase 2a, double-blind, placebo-controlled, randomized, proof-of-concept study evaluating LSTA1 when added to standard of care (temozolomide) versus temozolomide and matching LSTA1 placebo in subjects with newly diagnosed Glioblastoma Multiforme (GBM)
- Karelis, Guntis (Project leader)